astrazeneca glp 1 drug AstraZeneca's elecoglipron just posted some of the most closely watched Phase IIb data of the year and it landed at the right conference. Results from the VISTA and SOLSTICE trials, published simultaneously The future of GLP-1 drugs
Description
Feature Importance for ITE Estimation We applied SHAP values to identify the most influential features contributing to ITE variation
AS reports consultant fees from, Bayer, Eli Lilly Novo Nordisk and Sankyo, and lecture fees from Bayer, Eli Lilly, Novo Nordisk, and Sanofi-Aventis
Association between eating behavior patterns and the therapeutic efficacy of GLP-1 receptor agonists in individuals with type 2 diabetes: A multicenter prospective observational study
Portha, B., Tourrel-Cuzin, C
N Engl J Med 2023;389:51426.ArticlePubMed 66
